PFPengyang Feng

Pengyang Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pengyang Feng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Value of integrated 18F-FDG PET with fractional order calculus model-based MRI and DKI to evaluate the proliferation of lung squamous cell carcinoma

    by Zhun Huang, Nan Meng, Fangfang Fu, Yan Bai, Wei Wei, Ting Fang, Pengyang Feng, Ziqiang Li, Yu Luo, Jianmin Yuan, et al.

    18F-FDG-PET/MRI combines the functional and metabolic characteristics of PET with the good soft-tissue contrast of MRI. The results showed that high Ki-67-expressing tumors showed lower D and μ values and higher MK and SUVmax values. In addition, the diagnostic efficacy of all parameters is similar.

  • Lung cancer in multi-parametric PET/MRI: assessment of subtype and EGFR status based on amide proton transfer-weighted imaging and 18F-FDG PET

    by Nan Meng, Fangfang Fu, Pengyang Feng, Ziqiang Li, Zhun Huang, Ting Fang, Yaping Wu, Jianmin Yuan, Yang Yang, Hui Liu, et al.

    18F-Fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) allows multimodal quantitative MRI sequences to be scanned in parallel with PET imaging, providing a more multidimensional reflection of lesion information. Our results showed that amide proton transfer-weighted imaging (APTWI), and metabolism related parameters can be beneficial for the non-invasive assessment of subtype and EGFR status in patients with lung cancer.

  • Multi-parametric 18-FDG PET/MRI in predicting lung cancer lymphatic metastasis

    by Fangfang Fu, Meng Nan, Yaping Wu, Zhun Huang, Yan Bai, Pengyang Feng, Ting Fang, Jianmin Yuan, Yang Yang, Haiyan Gao, et al.

    It is meaningful to predict lymph node status of lung cancer before surgery. In the study, 18F-FDG PET/MRI were used to obtain PET metabolic parameters, multi-model DWI and APTWI parameters for predicting LNM of lung cancer. Our results showed that multiparametric PET/MRI is helpful in predicting lymph node status before surgery. 18F-FDG hybrid PET/MRI enables a robust diagnosis ability of LNM of lung cancer when several multi-model DWI parameters, PET metabolic parameters and APT parameter are combined. Thus, integrated PET/MRI can help to characterize LNM before surgery.

  • Non-invasive assessment of PD-L1 expression status in non-small cell lung cancer using multi-parametric 18F-FDG PET/MRI

    by Nan Meng, Fangfang Fu, Zhun Huang, Ziqiang Li, Yu Luo, Pengyang Feng, Yaping Wu, Jianmin Yuan, Yang Yang, Meiyun Wang

    18F-Fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) allows multimodal quantitative MRI sequences to be scanned in parallel with PET imaging, providing a more multidimensional reflection of lesion information. Our results showed that intravoxel incoherent motion (IVIM), amide proton transfer-weighted imaging (APTWI), and metabolism related parameters can be beneficial for the non-invasive assessment of PD-L1 expression in NSCLC patients, and the combination of SUVmax, D, and MTRasym(3.5ppm) may serve as a prognostic biomarker to guide immunotherapy.

  • Evaluation of Amide Proton Transfer‐Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters

    by Nan Meng, Fangfang Fu, Pengyang Feng, Ziqiang Li, Haiyan Gao, Yaping Wu, Jiawen Zhang, Wei Wei, Jianmin Yuan, Yang Yang, et al.

    Background: Lung cancer is one of the most devastating diseases worldwide, and it is meaningful to assess the subtype and epidermal growth factor receptor (EGFR) status in lung cancer noninvasively by imaging methods.Purpose: To differentiate noninvasively small cell lung cancer (SCLC) from nonsmall cell lung cancer (NSCLC), and EGFR mutation‐type from wild‐type NSCLC by comparing amide proton transfer‐weighted imaging (APTWI), diffusion‐weighted imaging (DWI), and 2‐[18F]‐fluoro‐2‐deoxy‐d‐glucose positron emission tomography (18F‐FDG PET).Study Type: Prospective.Population: A total of 99 patients with lung cancer.Field Strength/Sequence: APTWI and DWI at 18F‐FDG PET/MRI 3.0 T.Assessment: The apparent diffusion coefficient (ADC), magnetization transfer ratio asymmetry (MTRasym [3.5 ppm]), maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated and compared.Statistical Tests: Individual sample t‐test, Mann–Whitney U test, Logistic regression, and P < 0.05 were considered statistically significant.Results: In NSCLC, MTRasym (3.5 ppm), MTV, and TLG were significantly lower and ADC was significantly higher than in SCLC; MTRasym (3.5 ppm) was significantly higher and SUVmax, MTV, and TLG were significantly lower in EGFR mutation‐type NSCLC than in EGFR wild‐type NSCLC. In the identification of SCLC and NSCLC, MTRasym (3.5 ppm), ADC, and MTV were independent predictors, the AUCs of the combination of independent predictors, MTV, TLG, MTRasym (3.5 ppm), and ADC were 0.942, 0.875, 0.843, 0.814, and 0.687, respectively. In the identification of EGFR mutation‐type and wild‐type NSCLC, MTRasym (3.5 ppm) and MTV were independent predictors, the AUCs of the combination of independent predictors, TLG, MTV, MTRasym (3.5 ppm), and SUVmax were 0.919, 0.834, 0.813, 0.795, and 0.771, respectively.Data Conclusion: In the noninvasive assessment of lung cancer subtype and EGFR status, APTWI has similar utility to diffusion and metabolic parameters.Level of Evidence: 2Technical Efficacy Stage: 2


  • Application of Simultaneous 18F‐FDG PET With Monoexponential, Biexponential, and Stretched Exponential Model‐Based Diffusion‐Weighted MR Imaging in Assessing the Proliferation Status of Lung Adenocarcinoma

    by Zhun Huang, Xiaochen Li, Zhixue Wang, Nan Meng, Fangfang Fu, Hui Han, Dujuan Li, Yan Bai, Wei Wei, Ting Fang, et al.

    Background: Ki‐67 proliferation index (PI) is important for providing information on tumor behavior, treatment response, and prognosis. Integrated positron emission tomography/magnetic resonance (PET/MR) may have the potential to assess Ki‐67 PI in patients with lung adenocarcinoma.Purpose: To explore the value of simultaneous 18F‐fluorodeoxyglucose (18F‐FDG) PET/MR‐derived parameters in assessing the proliferation status of lung adenocarcinoma and to determine the best combination of parameters.Study Type: Prospective.Population: Seventy‐eight patients with lung adenocarcinoma and with Ki‐67 PI.Field Strength/Sequence: 3.0 T, simultaneous PET/MRI including diffusion‐weighted imaging (DWI) and 18F‐FDG PET.Assessment: DWI‐derived parameters, namely, apparent diffusion coefficient (ADC), true diffusion coefficient (D), pseudo diffusion coefficient (D*), perfusion fraction (f), diffusion heterogeneity index (α), and distributed diffusion coefficient (DDC); and PET‐derived parameters, namely, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolytic volume (TLG), were calculated and compared between the high (>25%) and low (≤25%) Ki‐67 PI groups. The correlations between PET‐derived parameters and DWI‐derived parameters were analyzed.Statistical Tests: Student's t‐test, Mann–Whitney U test, chi‐square test, and receiver operating characteristic (ROC) curves. A P‐value max, MTV, TLG, ADC, D, and DDC values were significantly different between the high (N = 35) and low Ki‐67 PI groups (N = 43). D, SUVmax, and MTV independently predicted the Ki‐67 PI status. The combination of D, SUVmax, and MTV had the largest area under the ROC curve (AUC = 0.900), which was significantly larger than the AUC alone of DDC (AUC = 0.725), SUVmax (AUC = 0.815), MTV (AUC = 0.774), or TLG (AUC = 0.783). The perfusion fraction did not correlate with SUVmax, MTV, or TLG (r = −0.03, −0.11, and −0.04, respectively; P = 0.786, 0.348, and 0.733).Data Conclusion: The combination of D, SUVmax, and MTV may predict Ki‐67 PI status. No correlation was observed between perfusion parameters and metabolic parameters.Level of Evidence: 1Technical Efficacy: Stage 2